Ascletis (01672) Publishes Monthly Return on Securities Movements for January 2026

Bulletin Express02-03

On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000 ordinary shares with a par value of USD 0.0001, totaling USD 700,000. No changes were recorded in authorized or issued share capital during the month.

As of 31 January 2026, the company had 991,874,320 issued shares (excluding treasury shares) and 7,084,210 treasury shares, summing to 998,958,530 total shares. The public float requirement was satisfied. No increase or decrease in either issued shares or treasury shares took place in January 2026.

Under the existing share option schemes, outstanding share options were unchanged, and there were no exercises resulting in new share issuance or treasury share transfers in January 2026. The warrants and other convertible instruments sections were marked not applicable. Repurchases of 800,000 shares in April 2025 and 4,986,000 shares between October and December 2025 remained not yet cancelled as of 31 January 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1136207146?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-03 19:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136207146","market":"hk","top_or_hot":-1,"title":"Ascletis (01672) Publishes Monthly Return on Securities Movements for January 2026","media":"Bulletin Express","content":"<p>On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000 ordinary shares with a par value of USD 0.0001, totaling USD 700,000. No changes were recorded in authorized or issued share capital during the month.</p>\n<p>As of 31 January 2026, the company had 991,874,320 issued shares (excluding treasury shares) and 7,084,210 treasury shares, summing to 998,958,530 total shares. The public float requirement was satisfied. No increase or decrease in either issued shares or treasury shares took place in January 2026.</p>\n<p>Under the existing share option schemes, outstanding share options were unchanged, and there were no exercises resulting in new share issuance or treasury share transfers in January 2026. The warrants and other convertible instruments sections were marked not applicable. Repurchases of 800,000 shares in April 2025 and 4,986,000 shares between October and December 2025 remained not yet cancelled as of 31 January 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ascletis (01672) Publishes Monthly Return on Securities Movements for January 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAscletis (01672) Publishes Monthly Return on Securities Movements for January 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-02-03 19:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000 ordinary shares with a par value of USD 0.0001, totaling USD 700,000. No changes were recorded in authorized or issued share capital during the month.</p>\n<p>As of 31 January 2026, the company had 991,874,320 issued shares (excluding treasury shares) and 7,084,210 treasury shares, summing to 998,958,530 total shares. The public float requirement was satisfied. No increase or decrease in either issued shares or treasury shares took place in January 2026.</p>\n<p>Under the existing share option schemes, outstanding share options were unchanged, and there were no exercises resulting in new share issuance or treasury share transfers in January 2026. The warrants and other convertible instruments sections were marked not applicable. Repurchases of 800,000 shares in April 2025 and 4,986,000 shares between October and December 2025 remained not yet cancelled as of 31 January 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01672","symbol_name":"歌礼制药-B","start_time":0,"source_url":"","article_id":"1136207146","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136207146","pubTimestamp":1770117954,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01672":"歌礼制药-B"},"translate_title":"歌礼(01672)公布2026年1月证券变动月报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01672":1},"content_text":"On 3 February 2026, Ascletis Pharma Inc. (stock code: 01672) released its Monthly Return for Equity Issuer for the period ended 31 January 2026. The authorized share capital remained at 7,000,000,000 ordinary shares with a par value of USD 0.0001, totaling USD 700,000. No changes were recorded in authorized or issued share capital during the month.\nAs of 31 January 2026, the company had 991,874,320 issued shares (excluding treasury shares) and 7,084,210 treasury shares, summing to 998,958,530 total shares. The public float requirement was satisfied. No increase or decrease in either issued shares or treasury shares took place in January 2026.\nUnder the existing share option schemes, outstanding share options were unchanged, and there were no exercises resulting in new share issuance or treasury share transfers in January 2026. The warrants and other convertible instruments sections were marked not applicable. Repurchases of 800,000 shares in April 2025 and 4,986,000 shares between October and December 2025 remained not yet cancelled as of 31 January 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136207146","isCrawlerRequest":true}